Main Article Content
Dyslipidemia is a risk factor in many health complications, among them is hypertension.
Case: This report presents a case of a poorly controlled dyslipidemia that could not be managed by medications. A surprisingly and an unexpected factor interfered; the triglyceride-lowering medication caused a significant increase in the appetite toward fat-rich food items which opposed its intended purpose.
Methodology: A dietary intervention and an uncommon drug dose modification were necessary. Results: The personally designed protocol led to a significant overall improvement and was successful in adjusting the biochemical parameters especially the plasma triglycerides and the total cholesterol and was effective in reversing hypertension and a pre-diabetic state to safer values. Conclusion: This is the first characterized case in the literature on the involvement of gemfibrozil in poor management of dyslipidemia.
Roy A, Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharm Immunot. 2009;31(3):339-351.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22(1):11-19.
O’Neill S, Bohl M, Gregersen S, Hermansen K, O’Driscoll L. Blood-Based biomarkers for metabolic syndrome. Trends Endocrinol Metab. 2016;27(6):363-374.
Sun D, Liu J, Xiao L, Liu Y, Wang Z, Li C, Jin Y, Zhao Q, Wen S. Recent development of risk-prediction models for incident hypertension: An updated systematic review. PLoS ONE. 2017; 12(10):0187240.
Anika UL, Pintaningrum Y, Syamsun A. Correlation between serum lipid profile and blood pressure in NTB General Hospital. J Hypertens. 2015;33:32.
Moreno-Fernández S, Garcés-Rimón M, Vera G, Astier J, Landrier JF, Miguel M. High fat/high glucose diet induces metabolic syndrome in an experimental rat model. Nutrients. 2018;10:1502- 1516.
Lithell H. Hypertension and hyperlipidemia: A review. Am J Hypertens. 1993;6(11): 303-308.
Herrod PJJ, Doleman B, Blackwell JEM, O’Boyle F, Williams JP, Lund JN, Phillips BE. Exercise and other nonpharmacological strategies to reduce blood pressure in older adults: A systematic review and meta-analysis. J Am Soc Hypertens. 2018;12(4):248-267.
Schwingshackl L, Chaimani A, Schwedhelm C, Toledo E, Pünsch M, Hoffmann G, Boeing H. Comparative effects of different dietary approaches on blood pressure in hypertensive and pre-hypertensive patients: A systematic review and network meta-analysis. Crit Rev Food Sci Nutr. 2019;59(16):2674-2687.
He FJ, MacGregor GA. Plasma sodium and hypertension. Kidney Int. 2004; 66(6):2454-2466.
Munoz JM, Sandstead HH, Jacob RA, Logan GM, Reck SJ, Klevay LM, Dintzis FR, Inglett GE, Shuey WC. Effect of some cereal brans and textured vegetable protein on plasma lipids. Am J Clin Nut. 1979;32:580-592.
Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007;7:24–29.
Houston MC, Harper KJ. Potassium, magnesium, and calcium: Their role in both the cause and treatment of hypertension. J Clin Hypertens. 2008;10(7):3-11.
Sun X, Veldhuizen MG, Wray AE, De Araujo IE, Sherwin RS, Sinha R, Small DM. The neural signature of satiation is associated with ghrelin response and triglyceride metabolism. Physiol Behav. 2014;136:63-73.
Kohanmoo A, Faghih S, Akhlaghi M. Effect of short- and long-term protein consumption on appetite and appetite-regulating gastrointestinal hormones, a systematic review and meta-analysis of randomized controlled trials. Physiol Behav. 2020;226. Article 113123.
Freire RH. Alvarez-Leite JI. Appetite control: Hormones or diet strategies? Curr Opin Clin Nutr Metab Care. 2020;23(5): 328-335.
Berthoud HR, Münzberg H, Morrison CD. Blaming the brain for obesity: Integration of hedonic and homeostatic mechanisms. Gastroenterology. 2017;152: 1728–1738.